Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Indian Journal of Medical and Paediatric Oncology
Search Article 
Advanced search 
Year : 1995  |  Volume : 16  |  Issue : 1  |  Page : 25-31

Experience with alpha 2-B interferon at medwin cancer centre, hyderabad, india-a preliminary report.

Dept of Oncology, Medwin Cancer Centre, Hyderabad, India

Correspondence Address:
G Sudarshan
Dept of Oncology, Medwin Cancer Centre, Hyderabad, India

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Intron-A(Fulford India Ltd.) is an alpha 2-B Interferon and it was introduced into the Indian market 2 years ago. Our aim was to record its usefulness in various malignancies. In total 21 cases received Intron A at our centre during the last 2 years period. This included 6 cases of Chronic Myeloid Leukemia(CML- in chronic phase); 6i cases of Multiple Myeloma Stage III(MM);2 cases of Renal Cell Carcinoma with lung secondaries(RCC); 2 cases of Non-Hodgkins Lymphoma-intermediate grade-Stage II(NHL) 2 cases of Oropharyngeal carcinoma(OC); one case of Myelofibrosis(MF) and 2 cases of Advanced Breast Cancer(ACB). The cases of CML, MM and NHL are still alive and disease free after 2 years of follow up. Both the RCC cases survived more than 1 year. One of the OC cases survived for one year. The MF case died due to pneumonia. The response in breast cancer was poor. Our experience reestablishes the fact that Interon A is useful in CML, MM and NHL. Its use in solid tumors is yet to be established.

[PDF Not available]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal